a more rapid course and worse prognosis. We consider that localized lesions need localized high dosage of radiation. There is then some chance of cure which may perhaps even be a lasting one. The most favourable types are those with primary lesions in the tonsil, tongue and nasopharynx. They are most appropriately dealt with by localized irradiation which includes the immediate lymphatic drainage areas.
The majority of cases of lymphosarcoma are very radiosensitive but some do not respond and in particular some cases of bone involvement have been found to be resistant.
Radiotherapy is of the greatest value as a palliative in some cases to obtain rapid relief of pressure symptoms.
We have used nitrogen mustard and other cytotoxic compounds with symptomatic improvement in cases with generalized disease.
Reticulum cell sarcoma has the worst prognosis of all. 20 % of our cases had local mucosal lesions in the mouth or pharynx which appeared as a sloughing ulcer or hypertrophic sloughing mass. It may occur primarily in the bowel wall or in mesenteric glands. 16 % presented as acute abdomen.
There may be skin lesions which may be nodular and localized or may be generalized with exfoliative dermatitis. Bone involvement may occur at any stage. They are the most rapid in their development and it may be possible to notice even a daily increase in size.
I consider that these cases should be treated on the same lines as I have suggested for lymphosarcoma. The majority are extremely radiosensitive but some do not respond to even high dosage.
My experience of giant follicular lymphoblastoma is limited to 26 cases: to the 16 cases referred to a further 10 have now been added. They have presented in almost all cases as a local glandular enlargement which may be a single node and may be large and conspicuous.
They tend to progress with involvement of mediastinal and abdominal glands with a tendency to serous effusions. All our cases have been markedly radiosensitive and they have been relatively benign over a number of years. Generalization does not appear to give the same bad prognosis as in the other types of reticuloses which I have discussed. They have not appeared to become more radioresistant if different groups of nodes become involved but some have changed into lymphosarcoma and some have developed a leukxemoid blood picture.
Summary I have suggested that in these conditions radiotherapy is indicated for localized disease and that chemotherapy should be reserved for generalized manifestations.
In Hodgkin's disease and in giant follicular lymphoblastoma radiotherapy will cause longer and more complete remission. In localized lymphosarcoma and reticulum cell sarcoma it gives a chance of cure.
For palliative purposes radiotherapy is usually more rapid and more certain in securing regression of a local mass.
Radiotherapy if used as a localized treatment, even if applied to multiple regions, is less likely to cause generalized damage and exhaustion of bone-marrow.
Both these methods have a valuable place and must be used in conjunction with one another.
The Management of Advanced Cancer
By Sir STANFORD CADE, K.B.E., C.B., F.R.C.S., F.R.C.O.G., M.R.C.P.
MANAGEMENT of advanced cancer is in many ways a greater problem than treatment of any given case. It includes the day-to-day supervision by the general practitioner as well as the highly specialized methods of treatment often needed for the control of pain and the maintenance of life.
Management varies from patient to patient and depends on the nature of the tumour, the site and distribution of lesions, the functional disabilities and the general effects, such as wasting, anxmia and fever.
The main object is the preservation of life with the minimum of symptoms and should result in objective and subjective alleviation.
Advanced cancer implies in all cases extension of disease beyond its site of origin to adjoining tissues and organs and always results in the end in a multiplicity of symptoms due to the metastatic spread. It presents an ever-varying clinical picture; a constant, although often slow, change of emphasis from one disability to another. Thus the management of any given patient often needs the services of different specialties and a different approach in the ;progressive stages of the disease. The available methods of treatment include surgery radiotherapy, chemotherapy, hormonal control, symptomatic relief by drugs and a combination of any of these therapeutic measures.
Surgery of Advanced Cancer In recent years many types of cancer have passed from the control of excisional surgery into the domain of other specialties. It is now recognized by many surgeons that even in common sites such as the breast, the uterus and the lung, the greatest benefits of excision are mainly, if not solely, in the early stages of the disease. Nevertheless, the paradoxical approach that major surgical ablations are only worth while in the earliest stages of the disease, is only true when complete and prolonged control of the disease can be reasonably anticipated. Thus the field of surgery has narrowed where the "curable" case is considered. The very great advances in surgical technique rendered possible by revolutionary developments in anesthesia, control of infection, blood-loss replacement and better understanding of the chemical needs of the body, have even more paradoxically widened the field of usefulness of surgery in some very advanced cases where previously surgery had nothing to offer.
Outstanding examples of surgical management of advanced cancer are the palliative resection of the cesophagus, multivisceral resections of the abdominal or pelvic viscera. Of these, pelvic viscerectomy is a good example of the application of operative methods to the so-called inoperable case. This procedure which entails the removal of all pelvic viscera, rectum, uterus, bladder, with or without the perineum and vulva, the establishment of a colostomy and a permanent urinary fistula is abundantly justified in a group of cases of advanced and extensive local disease but free from metastatic visceral spread. The justification of this procedure is the vastly increased comfort and a return to a near-normal life. It is chiefly indicated in the presence of vaginal-recto-vesical fistula with loss of control of the bowel and bladder and in the presence of uncontrollable discharge from what can best be described as a cloaca.
The appreciation that cancer of the breast and of the prostate are often not autonomous tumours but hormone-dependent has led to the remote control of disseminated mammary and ovarian cancer by gonadectomy, adrenalectomy or hypophysectomy. Gonadectomy is a simple, safe and minor procedure. In cancer of the prostate it presents many advantages over biochemical castration. It is speedy, simple, effective and devoid of the unpleasant sideeffects associated with cestrogen administration. In breast cancer it is effective for limited periods, varying from a few months to two or three years. Adrenalectomy has been rendered possible by the availability of cortisone and in the hormone-dependent cancers of the breast and prostate it is a valuable method in the control of disseminated cancer. Such cases with extensive skeletal or visceral disease, previously uncontrollable by treatment, can now, in a proportion of cases, be relieved of pain and disability and restored, nearly miraculously, to a tolerable and often symptomless existence.
Neurosurgical control of pain, by local section of nerves, cordotomy and leucotomy has a useful place in the management of severe and often uncontrollable pain. Its value is limited to a small group of patients but often renders the terminal stages reasonably comfortable.
Radiotherapy in Advanced Cancer A wide group of tumours in an advanced stage can be temporarily controlled by a variety of radiotherapeutic measures. Thus it is becoming more widely known that in Stage III cancer of the breast, radiotherapy offers much more than surgery. The rapidly growing, highly malignant, mammary cancer, often present only a few weeks or at the most a few months but already invading the lymph nodes and the lymph vessels, is seldom improved and more often than not made worse by attempts at surgical removal. Such cases can be controlled by radiotherapy sometimes for many years. As the majority of cases of breast cancer still present themselves for treatment in the later stages, radiotherapy is of value to a greater number of patients than surgery. The methods of treatment have altered and the availability of megavolt apparatus, from two million volts upwards, renders it possible to deliver to the tumour a very high dose of radiation with the minimum of damage to the normal tissues and often without any skin changes. The rapid treatment with conventional X-rays spread over three to four weeks is being replaced by a more prolonged overall treatment of two to three months. Technical developments, such as rotation therapy as well as the more powerful apparatus, including the 2 million electron volt generator, the 4 million linear accelerator and the 2,000 curie cobalt units now in clinical use, have rendered radiotherapy a more flexible method of treatment with a wider application, more effective and yet safer and less distressing to the patient.
Other groups of malignant tumours, such as Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and chronic leukeemias in early stages must be looked on as disseminated, generalized malignant processes even in the early stages. In the natural course of this group of neoplasms, only the early stages can be usefully treated by radiotherapy.
Localized metastatic skeletal deposits can be palliated by radiotherapy and relief from bone pain, healing of pathological fractures and recalcification of osteolytic lesions obtained.
Isotopes.-Artificial radioactive substances are replacing X-rays and radium as cobalt and caesium become available. The use of isotopes by injection or by mouth remains limited to a few types of lesions. The most commonly used isotopes are those of iodine, in the treatment of metastases from thyroid carcinoma, radioactive gold, by injection into the pleural or peritoneal cavities in some cases of malignant pleural effusion or ascites and radioactive phosphorus, in the management of polycythaemia and in a few and terminal cases of lymphosarcoma.
Chemotherapy in Advanced Cancer The value of cytotoxic agents in the management of advanced stages in the reticuloses and chronic leukiemias is now well established. Nitrogen mustard is of great palliative value in the late and apparently terminal stages of Hodgkin's disease. Remissions are obtained even when the liver and spleen are grossly enlarged, in the presence of continued or intermittent fever and when widespread lymph-node enlargement no longer responds to radiotherapy. Oral nitrogen mustard produced by Haddow has given encouraging results as maintenance therapy following a course of injections of nitrogen mustard. The oral substance has also proved of value in multiple myeloma either alone or in combination with cestrogens and has a retarding effect on disseminated malignant melanoma. Triethylene melamine (T.E.M.) has proved of temporary value in lymphosarcoma and in some cases of chronic lymphatic leukaemia, and remissions from three to twelve months have been obtained. T.E.M. has not proved of value in Hodgkin's disease, multiple myeloma, or in any form of carcinoma with the exception of some patients with bronchial carcinoma where favourable results have been reported. Myleran (Haddow) has given promising palliation in chronic myeloid leukemia for periods up to two years and is so far the only substance which can be considered as a substitute for radiotherapy.
In acute leukemias, folic acid antagonists (Aminopterin and related compounds) have given sporadically some temporary remissions in children. These substances, however, are of great toxicity and their use is not justified as the remissions are of very short duration.
Similar short remissions can be obtained without toxic effects by using ACTH or cortisone.
Hormones
Cancer of the breast and prostate are to date the only neoplasms where control of the disease can be achieved by hormones. The effect of hormones is palliative and temporary. Nevertheless it remains the greatest advance, so far, in the treatment of disseminated cancer in these sites, previously quite untreatable.
The value of hormones is limited to a proportion of patients as some neoplasms are hormone resistant. CEstrogens are useful in cancer of the prostate and in cancer of the breast in women but not in men. The use of oestrogens is further restricted to the older age group, well past the menopause. In pre-menopausal women and at the menopause, cestrogens are not advisable and in some patients produce acceleration of growth. Androgens are of value in mammary cancer in women but not in men. Both androgens and oestrogens can produce regression of the primary growth, and of metastasis both visceral and skeletal. Hormone dependence is not a permanent character of breast and mammary cancer and, in many patients, the tumours at first dependent become hormone resistant. All these observations indicate that although temporary control of the tumours can be achieved, it is unlikely that hormonal treatment will result in complete and permanent eradication of the disease. Control has been achieved for periods varying from three months to two years in most cases and in a few up to five years. Increased doses of hormones do not often result in increased periods of control.
For the past three and a half years bilateral adrenalectomy has been made possible by the availability of cortisone. More recently hormonal control by hypophysectomy has been proved to be a practical procedure. Both these major surgical procedures are at present undertaken in patients who are no longer benefited by the simpler methods of hormonal treatment and in whom the disease is widely disseminated. The choice between administration of hormones and adrenalectomy or hypophysectomy depends at present chiefly on the extent of the disease and the fact that there is no clinical or laboratory method by which the hormone-dependent cancer can be differentiated from the hormone-resistant one. Further, it is as yet too early to say how long the palliative effects of adrenalectomy or hypophysectomy are likely to last. If prolongation of life is limited to two or three years, postponement of the major surgical procedure is indicated as long as other methods of treatment are effective.
The most remarkable feature is the alleviation of pain obtained by hormones, especially in skeletal metastasis. Relief from pain is achieved very rapidly, in a few days; the mechanism of this is not understood.
Pain-relieving Drugs
In the terminal stages of cancer the need for pain-relieving drugs is essential; of these morphia and its derivatives remain the most important. Their use, however, should be postponed as long as other remedies can offer alleviation. Skeletal pain can be relieved by palliative X-ray therapy. Uncontrollable pain from involvement of nerves can be achieved by injections of nerves, cordotomy or leucotomy. Morphia and its derivatives should remain the last resort and their function in the end is to help the patient to die and, in massive doses, morphia shortens life.
The management of advanced cases of cancer is nearly always the responsibility of the family doctor. Specialized forms of treatment are of importance and often of value but the risks, discomforts and disabilities not infrequently associated with such treatment need to be considered from the general background of the individual patient, his mental distress, his fear of treatment which often is greater than the fear of the disease, the desire to live, the severity of symptoms, the age and the likely expectation of life.
The Management of Advanced Cancer By RICHARD ASHER, M.D., F.R.C.P.
Central Middlesex Hospital I HAvE no experience of treating advanced cancer beyond that which falls to the lot of any general physician. In cases of advanced cancer surgeons and physicians can give each other much assistance.
The technical advances of surgery and anesthesia allow much more massive surgical removals to be done and the discovery of new hormones allow more and more of the endocrine system to be taken away without killing the patient. I think it was Sir Henry Cohen who remarked here once "The feasibility of an operation is no indication for its performance", so, while admiring the skill of these surgical feats we must also pause to examine the fruits of victory and decide if they are worth the fight.
Firstly, radical surgery. In advanced cancer this is rarely possible. In deciding whether to attempt it, it is worth considering the mode of death without surgical treatment; death from carcinoma of the cesophagus for instance is so particularly unpleasant that there is much to favour attempting even a hazardous case. Another point concerns the commonness of a disease. Carcinoma of the lung is so common that doubtfully operable cases should not be sent to the thoracic surgery units when chest clinics and mass X-ray units are already finding so many early cases. If a man is pretty certain to die soon, the fewer bronchoscopies, bronchographies, biopsies and chest operations he has in his last few months the better. Secondly, palliative surgery-the severity of the symptoms which the operation is designed to palliate is the important factor. Jaundice, for instance, is sometimes a distressing death and cholecystogastrostomy well worth while. When I was a student Russell Howard taught us "It doesn't matter whether you die white or die yellow, but nobody likes to die scratching"; he thought the skin irritation the important thing but probably the other symptoms of jaundice including the depression are worth relieving in most cases. On the other hand a colostomy may sometimes produce as much distress as it relieves. Each case for palliative surgery is a separate problem and the doctor has to ask himself: How much distress is there? How much relief is the operation likely to give? How much distress is the operation likely to produce? Radiotherapy Though often responsible for many brilliant results radiotherapy has its disadvantages. First, some people guess they are suffering from cancer if they are treated with deep X-rays. Secondly, there are often severe general malaise and uncomfortable skin reactions. In my experience people with carcinoma of the lung often react badly to radiotherapy and the little span of life allotted to them is made less tolerable without being lengthened. The exception is where there is superior mediastinal obstruction. The relief of this by radiotherapy can be dramaticaUy rewarding.
If one includes chronic leukemias among the cancers I would observe here that radiotherapy should not be used too early, unless a patient's splenomegaly or adenopathy are mechanically a nuisance to him and unless he is anxmic. There is little point in producing dramatic changes in the size of his spleen or the number of his white cells, impressive though these are on paper. "Don't treat blood counts treat patients" is the motto. Many leukemic people, particularly the chronic lymphatics,. can attend for six-monthly observation without any treatment for several years, free of symptoms and in ignorance of the diagnosis.
